Biotech Showcase™ 2017: Unmet needs, uncommon commitment: The shift toward investment in rare diseas

January 17, 2017

Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candid, interactive and enlightening panel discussion about the evolving landscape in rare disease drug discovery and development. The panel discuss how approaches to rare disease research, drug development, commercialization and investment have changed in recent years, and why and how they’ve chosen to pursue leadership and innovation in rare diseases.

 


Alison Silva will be moderating a panel at BIO-Europe Spring in Barcelona this March 20-22, 2017 called "The business of rare disease company development" Learn more here 

Previous Video
Biotech Showcase™ 2017: The financial continuum and value creation
Biotech Showcase™ 2017: The financial continuum and value creation

Biotech financial markets were buffeted by the winds of macro-economic events in 2016 ranging from the Brex...

Next Video
BIO-Europe® 2016: InflaRX CEO highlights pipeline goals
BIO-Europe® 2016: InflaRX CEO highlights pipeline goals

Niels Riedemann, founder and CEO of InflaRX, speaks to Lucie Ellis, senior writer at Scrip, about the compa...